GEN Exclusives

More »

Tech Notes

More »
Sep 15, 2011 (Vol. 31, No. 16)

Getting Up to Speed on Label-Free Methods

Data-Analysis Tool Aims to Skirt Challenges that Have Hampered Technique in Past

  • Today, label-free is a frequently applied technology. Cellular assays are a major screening application as phenotypic cell changes can be observed without disturbing the native cells. Label-free instruments are used more and more with this application, which creates specific challenges for scientists running experiments. An intrinsic challenge is that the readout of all label-free instruments has no direct link to the biological process occurring in the cell.

    While the basic principles of data analysis for such plate-based, time-dependent experiments have been established, most available data-analysis platforms are restrictive when analyzing label-free data. They use only a part of the information content of the traces or require long data-analysis times compared to other screening technologies.

    Therefore, label-free analysis can create productivity and time drains and potentially undermine the value of screening lab output. This tutorial addresses how these challenges are overcome with a comprehensive and scalable data-analysis platform such as Genedata Screener® from Genedata.

  • Specifics of Label-Free Technologies

    Click Image To Enlarge +
    Figure 1. Kinetics traces from a Corning EPIC label-free instrument: There are six traces corresponding to six wells. Two traces correspond to a compound triggering the response of the Gs receptor, two traces to a compound activating the Gi/Gq receptor, and two traces correspond to no treatment (baseline). The trace pairs illustrate the different and characteristic responses of each receptor class: the Gi/Gq receptor shows a fast, yet temporary response reaching a peak at time frame number 8. In contrast, the Gs receptor shows a much slower signal increase, reaching its maximum at time frame 42.

    Label-free sensors measure the changes of cellular phenotypes by specific detection technologies such as impedance, surface plasmon, planar waveguide, or acoustic resonance. Readout changes are related to known and expected changes of the cellular phenotypes such as growth or shrinkage of cells, redistribution of intracellular masses, cellular shape changes, or changing orientation of cells to each other.

    A label-free experiment usually starts with measuring the signal of an experimental base status. When stimulating agents (e.g., compounds) are applied to the cells, the resulting phenotypic changes of the cellular phenotypes should cause a signal change. Both the phenotype of the base status (before addition of the compound) and the phenotypic change caused by the compound addition have to be verified external of the instrument (e.g., by verification through a microscope). The signal change corresponds to the difference between these two verified phenotypes.

    To better monitor and understand the relation between the signal change and the associated phenotypic change, additional measurements are recorded between the base line and a defined end time. The number and frequency of measurements are determined during assay development based on the confirmed phenotypic changes. Often, there is a specific signal expected between tzero and tend, e.g., a peak indicating a specific temporary, reversible change of the cells. Figure 1 shows example traces from Corning EPIC®.

    Simplified (and frequently applied) data-analysis methods just use maximum and base-line measurements. However, the important information in this example lies in the shape of the traces and needs to be used to obtain useful results.

    During assay development, experimental conditions and measurement frequencies are defined as well as the data analysis. This includes aggregation of the signal for defined time points (e.g., baseline: mean of first four measurements, peak: maximum signal of time points 12 to 20, etc.). However, during the actual screening experiment, deviations may occur.

    • The test substance shows an unexpected effect not captured by the controls used to calibrate the experiment.
    • The well shows unexpected issues (e.g., a strong artifact) that dominate the signal of the compound within.
    • Signals are shifted from plate to plate—both in strength and time.

    These issues are compounded as most screening platforms do not allow analysis of the full-time traces; they only import the aggregated results as defined during assay development. Results are calculated automatically (often in batch mode) by the software accompanying the label-free instrument. This situation has severe data-analysis consequences.

    •  It becomes next to impossible to see the actual time traces in the context of plate QC or hit-list creation. As a result, important trace trends go undetected reducing a lab’s successful result generation.
    • If aggregations must be adapted, data analysis starts from scratch. This requires a parameterization change in the instrument software followed by an export and re-import into the screening software. As a result, one sees inefficient screening, decreased productivity, and the potential for increased error rates.
    • When multiple instruments from different vendors are used in the same laboratory, different data aggregation and treatment methods are brought into the lab. As a result, there is inconsistent data processing.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »


Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?